OBJECTIVES: To evaluate changes in the quality of sleep and life of Chinese patients diagnosed with reflux esophagitis (RE) when treated with vonoprazan in real-world clinical practice.

METHODS: VIEW is a multicenter, single-arm, prospective, observational study (NCT04501627). Enrolled patients were ≥18 years and were treated with 20 mg vonoprazan QD for 4 weeks (8 weeks if insufficient healing). The effectiveness of vonoprazan (overall and for patients ≥65 years) was assessed using changes from baseline to week-4 in PRO scores: Pittsburgh Sleep Quality Index (PSQI, for sleep quality and patterns); the EuroQol 5-Dimension 5-Level (EQ-5D-5L, for quality of life); and the EQ-Visual Analogue Scale (EQ-VAS; for health status). Negative differences in PSQI and positive differences in EQ-5D-5L and EQ-VAS scores represent an improvement.

RESULTS: Of 1012 patients enrolled, 419 patients had a PSQI score at both baseline and week-4, and the mean±SD (95% CI) of the differences in the two scores was -0.6±2.27 (-0.83, -0.40). For 63 patients ≥65 years, the mean±SD difference was -0.5±2.47(-1.15, 0.10). The percentage (95% CI) of patients with poor sleep quality (global score >5) in the overall population decreased from 43.2% (39.01, 47.45) at baseline to 32.3% (27.88, 36.88) at week-4. In the ≥65 years age-group, this percentage decreased from 51.9% (40.36, 63.29) to 45.5% (33.14, 58.19). For 451 patients with EQ-5D-5L index scores at both baseline and week-4, the mean±SD of the differences was 0.028±0.0732 (0.0217, 0.0353). For 70 patients ≥65 years, the mean±SD of the differences was 0.041±0.072 (0.0242, 0.0587). For 452 patients with EQ-VAS scores at both baseline and week-4, the mean±SD of the differences was 5.1±11.52 (4.06, 6.19), while in 70 patients ≥65 years, the mean±SD of the differences was 8.5±14.69 (4.97, 11.97).

CONCLUSIONS: Vonoprazan treatment in real-world clinical practice improved both sleep quality and quality of life of Chinese patients diagnosed with RE.